Skip to content
Rutgers.edu
New Brunswick
RBHS
Newark
Camden
Online
Rutgers Health

Facebook
Twitter

Search

Search for: Hit enter to search or ESC to close

Institute for Translational Medicine and Science

Home
About
Investigator Resources
Clinical Trials Resources
Education & Training
Faculty
News
Contact Us

Select Page

Home / News / Rutgers Reports First Instance of COVID-19 Triggering Recurrent Guillain-Barré Syndrome / existing-drugs-could-stop-sars-cov-2-from-hijacking-cells-336798

existing-drugs-could-stop-sars-cov-2-from-hijacking-cells-336798

by | Jan 1, 2021

Recent Posts

New NJACTS Publication
New NJACTS Publication
New NJACTS Publication
New NJACTS Publication
Developing Doctors.

Archives

2023
- May
- April
- March
- February
- January
2022
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2021
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2020
- December
- November
- October
- September
- August
- July
2019
- September
2018
- July
- April
2017
- October
- April
2016
- September
- August
- March
- January
2015
- July
- February
2013
- November

Categories

News (1,749)

THIS SITE

Investigator Resources

Clinical Trials Resources

Education & Training

CONTACT US

Rutgers Institute for Translational Medicine and Science
Rutgers, The State University of New Jersey
Child Health Institute of New Jersey Building
89 French Street, Suite 4210
New Brunswick, NJ 08901

Facebook
Twitter

© 2019-2020, Rutgers Institute for Translational Medicine and Science. All rights reserved.| Privacy Policy

Rutgers, The State University of New Jersey, is an equal access/equal opportunity institution. Individuals with disabilities are encouraged to direct suggestions, comments, or complaints concerning any accessibility issues with Rutgers web sites to accessibility@rutgers.edu or complete the Report Accessibility Barrier or Provide Feedback Form.